Seminars in Oncology
Volume 33 , Pages 6-14 , February 2006

Role of Gemcitabine in Breast Cancer Management: An Update

  • Baldeep Wirk
    • ,
  • Edith Perez

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Edith Perez, Division of Hematology-Oncology and Breast Cancer Program, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224

References 

  1. Huang P , Chubb S , Hertel LW , et al.   Action of 2’,2’-difluorodeoxycytidine on DNA synthesis . Cancer Res . 1991;51:6110–6117
  2. Blackstein M , Vogel CL , Ambinder R , et al.   Gemcitabine as first-line therapy in patients with metastatic breast cancer (A phase II trial) . Oncology . 2002;62:2–8
  3. Brodowicz T , Kostler WJ , Moslinger R , et al.   Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer . Breast . 2000;9:338–342
  4. Carmichael J , Possinger K , Phillip P , et al.   Advanced breast cancer (A phase II trial with gemcitabine) . J Clin Oncol . 1995;13:2731–2736
  5. Spielmann M , Llombart-Cussac A , Kalla S , et al.   Single-agent gemcitabine is active in previously treated metastatic breast cancer . Oncology . 2001;60:303–307
  6. Possinger K , Kaufmann M , Coleman R , et al.   Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer . Anticancer Drugs . 1999;10:155–162
  7. Schmid P , Akrivakis K , Flath B , et al.   Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer . Anticancer Drugs . 1999;10:625–631
  8. Martin M . Platinum compounds in the treatment of advanced breast cancer . Clin Breast Cancer . 2001;2:190–208
  9. van Moorsel CJ , Veerman G , Bergman AM , et al.   Combination chemotherapy studies with gemcitabine . Semin Oncol . 1997;24: S7-17-S7-23
  10. Achanta G , Pelicano H , Feng L , et al.   Interaction of p53 and DNA-PK in response to nucleoside analogues (Potential role as a sensor complex for DNA damage) . Cancer Res . 2001;61:8723–8729
  11. Nagourney RA , Link JS , Blitzer JB , et al.   Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients . J Clin Oncol . 2000;18:2245–2249
  12. Burch PA , Mailliard JA , Hillman DW , et al.   Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer (A North Central Cancer Treatment Group Trial) . Am J Clin Oncol . 2005;28:195–200
  13. Fcps S , Alauddin Z , Rehman E , et al.   Gemcitabine and cisplatin combination chemotherapy as second-line treatment in patients with metastatic breast cancer . Proc Am Soc Clin Oncol . 2003;22:53; (abstr 212)
  14. Xu B , Li K , Liu D . Phase II trial of gemcitabine and cisplatin in anthracycline-resistant metastatic breast cancer . Proc Am Soc Clin Oncol . 2003;22:53; (abstr 211)
  15. Nasr FL , Chahine GY , Kattan JG , et al.   Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer . Clin Breast Cancer . 2004;5:117–122
  16. Binet S , Chaineau E , Fellous A , et al.   Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules . Int J Cancer . 1990;46:262–266
  17. Fumoleau P , Delgado FM , Delozier T , et al.   Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy . J Clin Oncol . 1993;11:1245–1252
  18. Romero A , Rabinovich MG , Vallejo CT , et al.   Vinorelbine as first-line chemotherapy for metastatic breast carcinoma . J Clin Oncol . 1994;12:36–41
  19. Gasparini G , Caffo O , Barni S , et al.   Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients (A phase II study) . J Clin Oncol . 1994;12:2094–2101
  20. Haider K , Kornek GV , Kwasny W , et al.   Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor . Breast Cancer Res Treat . 1999;55:203–211
  21. Valenza R , Leonardi V , Gebbia V , et al.   Gemcitabine and vinorelbine in pretreated advanced breast cancer (A pilot study) . Ann Oncol . 2000;11:495–496
  22. Stathopoulos GP , Rigatos SK , Pergantas N , et al.   Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer . J Clin Oncol . 2002;20:37–41
  23. Nicolaides C , Dimopoulos MA , Samantas E , et al.   Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy (A phase II study conducted by the Hellenic Cooperative Oncology Group) . Ann Oncol . 2000;11:873–875
  24. Bissery MC . Preclinical pharmacology of docetaxel . Eur J Cancer . 1995;31A:S1–S6 (suppl 4)
  25. Valero V . Docetaxel as single-agent therapy in metastatic breast cancer (Clinical efficacy) . Semin Oncol . 1997;24: S13-11S-13-18
  26. Burris HA . Single-agent docetaxel (Taxotere) in randomized phase III trials . Semin Oncol . 1999;26:1–6
  27. Mavroudis D , Malamos N , Alexopoulos A , et al.   Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine (A multicenter phase II trial) . Greek Breast Cancer Cooperative Group. Ann Oncol . 1999;10:211–215
  28. Fountzilas G , Nicolaides C , Bafaloukos D , et al.   Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer (A Hellenic Cooperative Oncology Group Phase II study) . Cancer Invest . 2000;18:503–509
  29. Laufman LR , Spiridonidis CH , Pritchard J , et al.   Monthly docetaxel and weekly gemcitabine in metastatic breast cancer (A phase II trial) . Ann Oncol . 2001;12:1259–1264
  30. Alexopoulos A , Tryfonopoulos D , Karamouzis MV , et al.   Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer . Ann Oncol . 2004;15:95–99
  31. Chen JG , Yang CP , Cammer M , et al.   Gene expression and mitotic exit induced by microtubule-stabilizing drugs . Cancer Res . 2003;63:7891–7899
  32. Clemons M , Leahy M , Valle J , et al.   Review of recent trials of chemotherapy for advanced breast cancer (The taxanes) . Eur J Cancer . 1997;33:2183–2193
  33. Seidman AD , Reichman BS , Crown JP , et al.   Paclitaxel as second and subsequent therapy for metastatic breast cancer (Activity independent of prior anthracycline response) . J Clin Oncol . 1995;13:1152–1159
  34. Murad AM . Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer . Oncology (Huntingt) . 2003;17:26–32
  35. Delfino C , Caccia G , Gonzales LR , et al.   Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer . Oncology . 2004;66:18–23
  36. Paridaens R , Biganzoli L , Bruning P , et al.   Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer (A European Organization for Research and Treatment of Cancer Randomized Study with cross-over) . J Clin Oncol . 2000;18:724–733
  37. Albain KS , Nag S , Calderillo-Ruiz G , et al.   Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC) (First report of overall survival) . Proc Am Soc Clin Oncol . 2004;22:14S; (abstr 510)
  38. Rothenberg ML , Sharma A , Weiss GR , et al.   Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors . Ann Oncol . 1998;9:733–738
  39. Colomer R , Llombart-Cussac A , Lluch A , et al.   Biweekly paclitaxel plus gemcitabine in advanced breast cancer (Phase II trial and predictive value of HER2 extracellular domain) . Ann Oncol . 2004;15:201–206
  40. Vici P , Foggi P , Capomolla E , et al.   Biweekly paclitaxel/gemcitabine (P/G) as salvage treatment in breast cancer patients (pts) (Preliminary results) . Proc Am Soc Clin Oncol . 2002;21:61b; (abstr 2054)
  41. Garle PA , Calvo L , Mayordomo JI , et al.   Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer (MBC) (Final results of a phase II study conducted within the Breast Cancer Investigation Spanish Group (GEICAM)) . Proc Am Soc Clin Oncol . 2003;22:50; (abstr 201)
  42. Mavroudis D , Malamos N , Polyzos A , et al.  Breast Cancer Committee of the Hellenic Oncology Research Group (HORG)   A multicenter phase II study of docetaxel plus gemcitabine biweekly administration as first-line treatment in patients with metastatic breast cancer (MBC) . Proc Am Soc Clin Oncol . 2003;22:65; (abstr 259)
  43. Kornek GV , Haider K , Kwasny W , et al.   Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor . Clin Cancer Res . 2002;8:1051–1056
  44. Pelegr A , Calvo L , Mayordomo JI , et al.   Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer (Preliminary results from a phase II trial) . Semin Oncol . 2004;31:20–24
  45. O’Shaughnessy JA , Vukelja S , Marsland T , et al.   Phase II trial of trastuzumab plus gemcitabine in chemotherapy-treated patients with metastic breast cancer . Clin Breast Cancer . 2004;5:142–147
  46. Colomer R , Mayordomo JI , Calvo L , et al.   Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer . Proc Am Soc Clin Oncol . 2004;23:61; (abstr 740)
  47. Polyzos A , Mavroudis D , Boukovinas J , et al.  Breast Cancer Working Group   A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2 . Proc Am Soc Clin Oncol . 2004;23:58; (abstr 728)
  48. Perez EA , Vogel CL , Irwin DH , et al.   Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer . J Clin Oncol . 2001;19:4216–4223
  49. Seidman AD , Berry D , Cirrincione C , et al.   CALGB 9840 (Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC) . J Clin Oncol . 2004;22:14S; (abstr 512)
  50. Khoo K-S , Zaidi M , Srimuninnimit V , et al.   Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC) . J Clin Oncol . 2004;22:14S; (abstr 710)
  51. Blum JL , Savin MA , Edelman G , et al.   Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel . J Clin Oncol . 2004;22:14S; (abstr 543)
  52. Conte PF , Donati S , Gennari A , et al.   Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer (A phase II study) . Br J Cancer . 2005;93:406–441
  53. Zielinski C , Beslija S , Mrsic-Krmpotic Z , et al.   Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer (A Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase II trial) . J Clin Oncol . 2005;23:1401–1408

 Funding for this work was partially provided by the Breast Cancer Research Foundation.Dr Perez has received grant support from Bristol-Myers Squibb, Sanofi-Aventis, Elli Lilly and Company, Pfizer, Roche, and Genentech Inc.

PII: S0093-7754(05)00327-1

doi: 10.1053/j.seminoncol.2005.07.028

Seminars in Oncology
Volume 33 , Pages 6-14 , February 2006

Article Tools